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Abstract
Background: Typically, subgroup analyses in clinical trials are conducted by comparing the intervention effect in
each subgroup by means of an interaction test. However, trials are rarely, if ever, adequately powered for
interaction tests, so clinically important interactions may go undetected. We discuss the application of Bayesian
methods by using expert opinions alongside the trial data. We applied this methodology to the VeRDiCT trial
investigating the effect of preoperative volume replacement therapy (VRT) versus no VRT (usual care) in diabetic
patients undergoing cardiac surgery. Two subgroup effects were of clinical interest, a) preoperative renal failure and
b) preoperative type of antidiabetic medication.
Methods: Clinical experts were identified within the VeRDiCT trial centre in the UK. A questionnaire was designed
to elicit opinions on the impact of VRT on the primary outcome of time from surgery until medically fit for hospital
discharge, in the different subgroups. Prior beliefs of the subgroup effect of VRT were elicited face-to-face using
two unconditional and one conditional questions per subgroup analysis. The robustness of results to the
‘community of priors’ was assessed. The community of priors was built using the expert priors for the mean
average treatment effect, the interaction effect or both in a Bayesian Cox proportional hazards model implemented
in the STAN software in R.
Results: Expert opinions were obtained from 7 clinicians (6 cardiac surgeons and 1 cardiac anaesthetist).
Participating experts believed VRT could reduce the length of recovery compared to usual care and the greatest
benefit was expected in the subgroups with the more severe comorbidity. The Bayesian posterior estimates were
more precise compared to the frequentist maximum likelihood estimate and were shifted toward the overall mean
treatment effect.
Conclusions: In the VeRDiCT trial, the Bayesian analysis did not provide evidence of a difference in treatment effect
across subgroups. However, this approach increased the precision of the estimated subgroup effects and produced
more stable treatment effect point estimates than the frequentist approach. Trial methodologists are encouraged to
prospectively consider Bayesian subgroup analyses when low-powered interaction tests are planned.
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Background
In clinical trials, evaluation of intervention effects in sub-
groups of patients may be pre-specified in the study
protocol, or exploratory analyses carried out post-hoc.
The aim of such analyses is to assess if the intervention
effect is consistent across patients or if specific sub-
groups of patients experience larger benefit or harm.
Typically, subgroup analyses in clinical trials are con-
ducted by comparing the intervention effect in each sub-
group by means of an interaction test in the frequentist
framework. In trials reporting subgroup analyses, be-
tween 27 and 34.5% planned a statistical test for inter-
action [1–3]. When the test does not provide evidence
of an interaction, it is recommended to report the over-
all results. However, these tests are low-powered and
clinically important interactions in subgroup of patients
may go undetected. In light of this, some suggest raising
the Type I error rate when testing interactions, thereby
increasing power but this is offset by the increased risk
of “false positives” and chance findings [4].
A Bayesian analysis differs from the frequentist ana-
lysis in that the uncertainty about unknown parameters
such as an interaction parameter can be expressed in a
‘prior’ distribution. Instead of assuming that there is no
prior knowledge about the interaction effect, or assum-
ing that there is no interaction by pooling all patients to-
gether irrespective of their subgroup, the proposed
Bayesian approach allows the user to flexibly apply an
expert informative prior for the interaction parameter
using external knowledge to the trial [5]. Data from pre-
vious studies and/or expert opinions can be used in a
prior to characterise the possibly differential effects of an
intervention for subgroups of patients having different
comorbidities. By Bayes’ theorem, inferences about the
subgroup treatment effects are drawn from the ‘poster-
ior’ distributions. The posterior distributions are propor-
tional to the product of the expert prior distributions
and the trial data also referred as the ‘likelihood’. The
interest of this method lies in situations where increas-
ing the power by collecting more patient-level data is
not feasible, too expensive or too time-consuming.
Motivating case study
The VeRDiCT study comprised two randomised con-
trolled trials conducted in parallel. The study investi-
gated the effect of volume replacement therapy (VRT)
on postoperative length of stay before being fit-for-
discharge. The population of interest were diabetic
patients undergoing coronary artery bypass grafting sur-
gery. The study randomised 169 patients (122 in the UK
and 47 in India). Two subgroup effects were of clinical
interest, a) preoperative renal function and b) preopera-
tive blood glucose management. In relation to subgroup
a), VRT effect was compared in patients with evidence
of either microalbuminuria or diabetic nephropathy to
patients without (low risk of renal failure subgroup A1
versus high risk subgroup A2). With respect to subgroup
b), the analysis compared patients managing their dia-
betes only with oral medication (less severe comorbidity
subgroup B1) to patients taking only insulin or com-
bined with oral medication (more severe comorbidity
subgroup B2). One hundred and seventy participants
were required in order to detect a significant interven-
tion effect in the combined trial population using fre-
quentist methods. Recruiting as many in each subgroup
was not feasible as the intervention is very specialised
and would have extended the recruitment period by
more than 4 years of recruitment. Hence, the aim of this
study was to apply a Bayesian approach to analyse the
subgroup effects in the VeRDiCT trial, and demonstrate
how this approach can provide more power to detect
treatment effects and additional insights to interpreting
subgroup effects compared to the frequentist framework.
Methods
Prior elicitation and expert opinion derivation
An extensive literature is available on elicitation
methods and associated heuristics that may bias an ex-
pert’s ability to assess probabilities [6–9]. Examples of
elicitation questionnaires in medical trials have been
published [10–13]. Our questionnaire was specifically
produced for this study (see Additional file 1) and is
based on the work of Spiegelhalter et al. [14]. Experts
were identified as health professionals well informed
about VRT and effects in diabetic patients undergoing
CABG surgery. Cardiac surgeons and cardiac anaesthe-
tists were identified within the UK trial site. The ques-
tionnaire was delivered face-to-face and as part of a
routine research meeting before the results of the VeR-
DiCT trial were available. As hazards are complex to
elicit, experts were asked about the number of patients
they would expect to be fit-for-discharge within 6 days
post-operation. Six days post-operation was determined
as the median length of stay for diabetic patients under-
going CABG surgery between 2012 and 2015 from the
Patient Analysis and Tracking System (PATS) database
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– a registry of every adult cardiac surgical procedure
undertaken at the Bristol Royal Infirmary cardiac surgi-
cal unit. Being fit-for-discharge within 6 days was de-
fined as the outcome in the questionnaire as a ‘normal’
recovery without any major complications.
The experts were asked to express their opinions in
the quantile format as suggested by Cooke [15, 16]. Ex-
perts provided percentiles of their subjective distribution
using the median, 2.5 and 97.5 percentiles (i.e. the most
likely value, the lowest and highest plausible values re-
spectively). Experts were encouraged to imagine as if
they would have to provide bounds of a 95% range of
plausible values.
The questionnaire answers were used as prior beliefs
for the hazard ratios. Hence a transformation was re-
quired to convert the opinions to the log hazard ratio
scale:
log HRð Þ ¼ log log 1 − p1ð Þ
log 1 − p2ð Þ
 
where p1 and p2 are the probabilities of having a nor-
mal recovery in the VRT group and usual care group
respectively.
A positive log(HR) (i.e. HR > 1) suggests that the ‘haz-
ard’ of having a normal recovery is higher and therefore,
favours the VRT group compared to the usual care
group. The log(HR) was assumed to follow an approxi-
mate normal likelihood distribution. Each expert’s elic-
ited opinions were fitted with normal distributions using
least squares on the cumulative distribution function
[17]. The experts’ individual distributions were then ag-
gregated to obtain a combined experts prior distribution
using the linear opinion pooling method [18].
The intervention effects on the log hazard ratio scale
are denoted θ1 and θ2 for the less and more severe sub-
groups respectively such that θ1  Nðp1; s21Þ and θ2  N
ðp2; s22Þ. Experts were firstly asked to provide their opin-
ions about the number of patients treated with VRT
having a normal recovery in the less and more severe
subgroups separately in each unconditional question.
This was then followed by a conditional question which
asked the experts how their opinions changed about the
effect in the more severe subgroups given two scenarios
in the less severe subgroups. The two scenarios were: a)
if we knew the true effect in the less severe subgroup is
null (i.e. θ1 = 0); and b) if we knew the true effect in the
less severe subgroup is beneficial by a value d (i.e. θ1 = d,
d > 0). The following distributions were derived: θ2 j ðθ1
¼ 0Þ  Nðp20; s220Þ and θ2 j ðθ1 ¼ dÞ  Nðp2d; s22dÞ . For
the risk of renal failure subgroup analysis, the beneficial
change was d ¼ log½ logð1 − 70=100Þlogð1 − 60=100Þ meaning we supposed
that in truth VRT increased the number of patients with
low risk of renal failure having a normal recovery to 70
compared to 60 when treated with usual care. For the
blood glucose management subgroup analysis, the
change was d ¼ log½ logð1 − 65=100Þlogð1 − 50=100Þ. The joint prior distri-




was modelled as a bivariate Normal with mean m = (p1,
p2) and variance-covariance matrix V ¼ V 11 V 12V 12 V 22
 
.
The parameter derivations followed the methods out-
lined by White et al. [19]:
1. The unconditional variance V11 for the effect of
VRT in the less severe subgroup was derived from
the variance of the elicited distribution: V 11 ¼ s21.
2. The covariance element V12 was derived as V12 =
b12V11. The regression coefficient (b12) of the
treatment effect in the more severe subgroup on
the treatment effect in the less severe subgroup is
defined as b12 ¼ p2d − p20d − 0 .
3. The variance of the treatment effect in the more
severe subgroup V22 is derived such that V 22
¼ varðθ2jθ1Þ þ b212 V 11. The variance of the
treatment effect in the more severe subgroup
conditional on the treatment effect in the less
severe subgroup was derived as the average of the
two conditional question variances: varðθ2jθ1Þ
¼ s220þs22d2 . A sensitivity analysis assuming the
variance V 22 ¼ s22 was performed to compare
posterior estimates to alternative variance
derivations when the resulting variance-covariance
was positive definite.
4. A further sensitivity analysis was performed by
drawing the mean of θ2 from the regression
E(θ2| θ1) = p20 + b12θ1, giving E(θ2) = p20 + b12p1.
Community of prior specifications
This paper assessed results from a wide variety of expert
opinions and ways of using the expert opinions. A clin-
ical prior, a sceptical prior, an interaction prior, and
other specifications of the expert opinions composed
our ‘community of priors’ and are described below:
 The clinical prior was directly derived from the
experts’ opinions: θ~N2(m,V)
 The sceptical prior used the experts’ opinions for
the variance component, but the mean was centred
around the null effect: θ~N2(0, V)
 The interaction prior only used an informative
expert prior for the treatment-by-subgroup interac-
tions. This was enabled by re-parameterising θ such
that the prior ψ consisted of an uninformative prior
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for the mean average VRT effect and an informative
prior for the interaction term comparing the effect
in the more severe subgroup to that in the less se-
vere subgroup:









θ1 þ θ2ð Þ
θ2 − θ1
 !
The prior ψ variance is W = CVCT. The matrix W
was modified such that:
W  ¼ L 0
0 W 22
 
with L an arbitrarily large
number. L in W* expresses the lack of
information about the average treatment effect
whilst W22 expresses the prior information from
our experts about the interaction effect θ2 − θ1.
The off-diagonal elements express the absence of
any covariance beliefs between the average inter-
vention effect and the interaction effect. A matrix
V∗ was back transformed such that V∗ =
C−1W*C−T. The interaction prior followed
θ~N2(m, V
∗). The Bayesian analysis using the
interaction prior specification was defined as the
primary analysis of the VeRDiCT trial.
 A further specification of the interaction prior
θ~N2(0,V
∗) was assessed to avoid reporting
qualitative interactions (e.g. θ1 < 0 and θ2 > 0) in
specific cases where the treatment effects were null
in both subgroups but the experts believed VRT was
much better in the more severe subgroup than in
the less severe subgroup (i.e. θ2 − θ1 > 0).
 A vague prior that would closely reproduce the
results of a frequentist maximum likelihood estimate
(MLE): θ~N2(0, LI) where L is an arbitrarily large
number and I is the identity matrix. This prior
specification was added following comments from
clinical experts asking about the performance of the
Bayesian approach when there is no knowledge
about the subgroup effects. Table 1 presents a
summary of the community of priors and their
associated mean and variance parameters used to
assess posteriors results.
Statistical analysis
The VeRDiCT primary outcome was time-to-event and
was analysed using an adjusted Cox proportional haz-
ards model in the trial report [20]. A Bayesian counter-
part of the Cox proportional hazard model was
performed adjusting for the same covariates. Analyses
were performed using STAN software from R [21, 22]
and STATA version 15.1 (StataCorp LP, College Station,
TX, USA). White et al. proposed a normal-normal con-
jugate Bayesian analysis as the number of events was
large and therefore the log-likelihood was reasonably ap-
proximated by a normal distribution [19]. However, we
did not take this approach but jointly estimated the log-
likelihood and the prior in a fully Bayesian Cox model to
extend the proposed method to scenarios of low number
of events. The STAN code for this analysis is provided
in the supplementary materials (see Additional file 2).
As the experts were all from the UK site, the analysis
was restricted to the UK trial. The results of the Bayes-
ian analysis were compared with the frequentist ap-
proach to assess relative merits of each statistical
framework.
Results
VeRDiCT trial and expert results
Table 2 presents baseline characteristics of the 121 par-
ticipants who underwent randomisation in the UK trial
of the VeRDICT study. The baseline characteristics were
similar across treatment groups. The pre-surgery blood
glucose management presents a slight imbalance with a
higher proportion of patients managing their blood glu-
cose with oral medication in this those randomised to
VRT compared to patients randomised to usual care.
Apart from the opinion of expert A, the unanimous be-
lief was that VRT was better or at least not worse than
usual care for all subgroups of patients (Fig. 1). Add-
itionally, the experts believed that VRT would provide
the greatest benefit for higher risk patients with more se-
vere comorbidities. For example, patients with high risk
of renal failure or patients treated with insulin ± oral
medication were expected to have 20% higher ‘hazard’ of
a normal recovery with VRT compared to usual care
(HR = 1.20, 95% CI 0.95–1.51 and HR = 1.20, 95% CI
Table 1 Summary of prior specifications
Prior
specifications
Mean parameter Variance parameters
Mean effect Interaction effect
Clinical m Va Va
Sceptical 0 Va Va
Interaction m V*b V*a
Interaction-variance 0 V*b V*a
Vague 0 LIb LIb
aInformative using expert opinions bUninformative
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0.99–1.46 respectively). Nonetheless, the combined ex-
perts’ prior (presented in black) still includes the null ef-
fect suggesting there is some uncertainty about VRT
being better than usual care
Bayesian analysis results
The results of the Bayesian analyses combining the
trial data and the expert opinions were very similar
for both subgroup analyses A and B: the trial data
treatment estimates (MLEs) and the expert opinions
(prior medians) were of the comparable magnitude
and direction in the risk of renal failure analysis (left
panel) compared to the blood glucose management
subgroup analysis (right panel) in Fig. 2. Hence for
the following results, we have focused on the risk of
renal failure subgroup analysis.
While the experts believed that VRT would be of
greater benefit in the higher risk subgroup (shown in
black), this was not borne out of the trial data (grey); the
maximum likelihood hazard ratio was lower in the high-
risk group than in the low-risk group. The posterior re-
sults using an expert prior for the interaction effect but
a vague prior for the mean effect (i.e. the interaction
prior shown in blue) produces a slope that is similar to
that of the prior but shifted towards the trial’s mean
treatment effect (HR = 1.07). The clinical posterior esti-
mates are closely aligned to the prior, in location and in
slope, as it uses the expert beliefs for both the overall
mean and the interaction effects. This result suggests the
clinical prior dominates the trial data when using in-
formative priors for both the interaction effect and the
mean effect. The slopes of the posterior estimates using
the sceptical and the interaction-variance priors lie be-
tween the MLE and the prior, with their location centred
around the null effect and the mean treatment effect
respectively.
Figure 3 presents the prior median, MLE and poste-
riors estimates for the risk of renal failure subgroup
analysis and their variability. In this trial, the 95%
confidence intervals for MLE are wide (e.g. 95% CI
0.63–2.08 and 95% CI 0.45–1.98 for A1 and A2 sub-
groups respectively) due to small subsamples (75 pa-
tients in subgroup A1, 45 in A2, 65 in B1 and 56 in B2).
The variability of the combined experts’ prior distribu-
tion was lower than the variability in the trial treatment
effect MLEs.
The Bayesian posterior results using expert beliefs
have increased precision compared to the MLE. In the
presence of a qualitative interaction (i.e. the treatment
effects in the subgroups are in opposite directions)
which was observed in the trial data MLEs, the posterior
estimates using the interaction prior are pulled towards
the mean treatment effect. The precision of the esti-
mates is increased but the results do not provide enough
evidence of a benefit of VRT (52 and 67% probability of
VRT being better than usual care for less and more se-
vere subgroup respectively). Using each expert prior in-
dividually gave posterior estimates which varied across
experts. The posterior estimates using expert A’s prior,
who was the most sceptical about VRT, favours usual
care, with probabilities of only 5 and 15% of benefit with
VRT in the less and more severe subgroups respectively.
In contrast, experts E and F were very enthusiastic about
the effect of VRT and the posterior estimate reports a
100% probability of VRT being better for both
subgroups.
The posterior estimates using the vague prior confirms
that when using uninformative priors for all the parame-
ters, the results are consistent with the MLEs that only
use trial data for inferences. Although the posterior re-
sults were robust to the different variance derivation, the
posterior results using the conditional mean derivation
returned point estimates that were different compared
to the unconditional mean derivation (HR = 1.05 vs
HR = 1.01 in the low risk subgroup and HR = 1.06 vs
HR = 1.12 in the high risk subgroup). We argue the prior
mean of θ2 derived from the experts’ answers to the
second unconditional question is a direct derivation
Table 2 Baseline characteristics of the UK VeRDiCT trial participants
Treatment allocation Randomised to usual care (n = 61)
n (%)
Randomised to VRT (n = 60)
n (%)
Minimisation criteria
Age > 70 years 17 (28) 17 (28)
Female gender 10 (16) 10 (17)
Preoperative creatinine > 160 μmol/L 3 (5) 4 (7)
Ejection fraction < 50% 49 (80) 49 (82)
Cardiac angiogram in the 5 days prior to surgery 5 (8) 7 (12)
Subgroup variables
Low risk of renal failure 37 (62)a 38 (63)
Oral diabetic medication only 30 (49) 35 (58)
aOne patient with missing data
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requiring less manipulation than the conditional mean
derivation and therefore the unconditional method
should be preferred. The posteriors results estimates are
provided in the supplementary files (see
Additional file 3).
Discussion
A Bayesian approach to subgroup analyses has been suc-
cessfully applied to the UK VeRDiCT trial. Expert opin-
ions were elicited without knowledge of the trial results
and these opinions were combined with the trial data
Fig. 1 Elicited prior distributions of the log hazard ratio. The elicited prior distribution are presented for each expert and for the combined prior,
for the risk of renal failure subgroups (a) and for the type of antidiabetic medication subgroups (b)
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Fig. 2 Expert prior median and posterior median estimates using the pooled expert prior with different specifications
Fig. 3 VeRDiCT Bayesian results: intervention effect comparing VRT to usual care in subgroups A. Prior median and 95% Interval, MLE estimate
and 95% confidence intervals, and posterior medians and 95% credible intervals for the treatment effect in the risk of renal failure subgroups
are presented
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under a range of prior specifications. The questionnaire
eliciting opinions was challenging to design as it needed
to not be overburdensome but at the same time capture
the information required (i.e. personal opinions on the
effect of VRT in each subgroup and the interaction ef-
fect between the intervention and the subgroups). Face-
to-face elicitation had the advantage that training and
feedback could be provided to the experts iteratively.
Other elicitation methods (e.g. postal questionnaires)
were considered but we chose a face-to-face approach to
allow us the opportunity to answer questions and clarify
what was being asked where required. As previously re-
ported [23–25], experts experienced challenges when
characterising a range of plausible values and the elicit-
ation range may influence how they express their opin-
ion. The Bayesian methods offer a formal framework to
quantify clinical opinions and use them when relevant
historical data is not available. It also provides an oppor-
tunity to assess how using the expert opinions under dif-
ferent assumptions of the community of priors impacts
the results. The sensitivity of results to alternative expert
opinion derivations were also assessed and were helpful
in identifying whether various mean and variance par-
ameter derivation choices impact the posterior estimates
in the context of this trial.
The primary Bayesian analysis results using the inter-
action prior suggests there is insufficient evidence in
favour of VRT being better than usual care. In this
sense, the Bayesian analysis is consistent with the fre-
quentist analysis and suggests further research is needed
to claim any subgroup effects. The elicitation results in-
dicated that experts believed VRT was better than usual
care, and that the effect would be greatest for patients
with more severe comorbidities. These opinions were
not supported by the trial data, which suggested VRT
was worse than usual care for participants with more se-
vere comorbidities. It is unclear whether this inconsist-
ency is due to ‘inaccurate’ expert opinions or spurious
findings from the frequentist analysis which is suscep-
tible to outliers given the small sample size.
Trial reporting guidelines advocate against presenting
subgroups estimates if the interaction test is not signifi-
cant [26]. However, this recommendation also prevents
us from understanding the effect of an intervention in
subgroups of interest. Using an informative prior for the
interaction parameters (i.e. the interaction and
interaction-variance priors) and an uninformative prior
for the overall mean treatment effect in the Bayesian
analysis allows us to draw inferences for both subgroups.
By ‘borrowing’ information from the treatment effect in
the complementary subgroup, subgroup posterior esti-
mates using the interaction priors were more stable (less
extreme point estimates and higher precision) than fre-
quentist subgroup estimates. Our proposed Bayesian
subgroup model shifts point estimates and their associ-
ated credible intervals towards the overall mean effect,
whereas classical frequentist approaches keep the point
estimate fixed and adjust for multiple comparisons by
making the confidence intervals wider. Analyses model-
ling the treatment effects in a joint model have been re-
ported to be sensible approaches to multiplicity as
multiple treatment inferences are directly incorporated
in the model [27, 28]. To maximise the use of the trial
data, we encourage methodologists to prospectively con-
sider Bayesian subgroup analyses using expert opinions
when several low-powered subgroup analyses are
planned.
Our study had several strengths but also some limita-
tions. First, we have identified experts within one trial
centre, which may have introduced bias insofar that our
experts probably had similar opinions that may not re-
flect all experts’ opinions on the effect of VRT. Also, we
restricted the analysis to the UK expert opinions and
only included data from the UK centre in this case
study. The rationale for this was that it was impractical
to elicit experts from the centre in India. Ideally, opin-
ions would be elicited from experts from several sites of
a multicentre trial, which can then be incorporated in a
hierarchical Bayesian model. Furthermore, we could
have elicited opinions from more experts, although there
is no consensus on the number of expert opinions re-
quired. Previous studies have used as few as one expert
[29] and as many as 37 experts [10]. The number of ex-
perts will typically depend on the number of available
experts in your field. Fewer thoughtful opinions are
more valuable than a higher number of opinions from
less engaged experts [30].
Second, it is recognised that the quality of the inter-
views is important in determining participant responses.
We used a simple questionnaire and piloted it, but it is
possible that a more in-depth interviews undertaken by
a non-statistician would have elicited different responses.
Audio recording interviews that are then independently
assessed for quality a second opinion of their content
could be a useful addition [31].
Third, the approach to Bayesian subgroup analysis re-
ported here is similar to that conducted by White et al.
[19]. In that study the expert opinions had little impact
on the posteriors as each of the three subgroups were
adequately powered to detect subgroup treatment ef-
fects. The Bayesian approach is of greatest value and im-
pact when the study is under-powered for subgroup
analyses.
Fourth, introducing prior expert opinions in several
different specifications generated more precise posterior
estimates and a shift of the point estimates compared to
the MLEs in the VeRDiCT trial. An increase in precision
and shift of the estimate away from the null increases
Thirard et al. BMC Medical Research Methodology          (2020) 20:300 Page 8 of 10
the power to detect a treatment effect, but at the cost of
bias in the treatment estimate. An extension of the pro-
posed methodology could investigate how clinical opin-
ions influence the posterior results of a Bayesian
subgroup analysis when the true subgroup treatment ef-
fects are known. A simulation study could investigate
the impact of the magnitude of the interaction effect and
sample sizes on statistical inferences by assessing the
trade-off between bias and power to detect a treatment
effect.
Conclusions
This Bayesian subgroup approach proves its value in
cases where fully powered subgroup analyses are not
feasible, time-consuming or too expensive. With limited
resources, experts can be elicited, and their opinions can
help maximise the trial data. Adding experts’ opinions to
the analyses could increase the precision of the treat-
ment estimate as we have noted in our motivating case
study which could in return increase power to detect an
effect. Still, and as any subgroup analysis, researchers
need to be cautious in appraising each posterior distri-
bution results, acknowledge the limitations of the find-
ings, and provide supporting or contradictory data from
other studies when available.
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